122957-29-3

Upstream product

• 104096-04-0 N-(4-iodophenyl)-2-nitroaniline 
• 636-98-6 p-nitrobenzene iodide 
• 1493-27-2 ortho-nitrofluorobenzene 
• 540-37-4 p-aminoiodobenzene 

Downstream Products

• 1010857-88-1 C₂₀H₂₄IN₃O₃ 

Relevant academic research and scientific papers

Selective Hydrogenation of Halogenated Nitroaromatics to Haloanilines in Batch and Flow

The selective hydrogenation of functionalized nitroaromatics poses a major challenge from both academic as well as industrial viewpoints. As part of the CHEM21 initiative (www.chem21.eu), we are interested in highly selective, catalytic hydrogenations of halogenated nitroaromatics. Initially, the catalytic reduction of 1-iodo-4-nitrobenzene to 4-iodoaniline served as a model system to investigate commercial heterogeneous catalysts. After determining optimal hydrogenation conditions and profiling performances of the best catalysts, hydrogenations were transferred from batch to continuous flow. Finally, the optimized flow conditions were applied to transformations which represent important steps in the syntheses of the active pharmaceutical ingredients clofazimine and vismodegib.

Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists

A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [125I]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay. The pharmacokinetic properties o

Lactol PAF antagonists

The invention encompasses compounds of general formula I: STR1 wherein W represents an imidazo[4,5-c]pyridyl group, optionally substituted with one or more substituents selected from C1 -C6 alkyl, C1 -C6 alkoxy, halo, CF, and CN; and Z, R1, R2, R3, R4, R5, R6 are variables. These compounds are useful as antagonists of platelet activating factor.

Platelet activating factor antagonists

Platelet activating factor antagonists of formula (I): STR1 wherein R is phenyl or phenyl substituted by one or more substituents selected from nitro, halo, C1 -C4 alkyl, C1 -C4 alkoxy, aryl (C1 -C4) alkoxy, fluoro (C1 -C4) alkoxy, C1 -C4 alkylthio, C1 -C4 alkylsulphonyl, hydroxy, trifluoromethyl and cyano, or is phenyl fused to a dioxole ring; R1 and R2 are each independently H or C1 -C6 alkyl, or R1 and R2 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl, N-(C1 -C4 alkyl) piperazinyl or N-(C2 -C4 alkanoyl)-piperazinyl group; or R2 is H or C1 -C4 alkyl and R1 is CN, C3 -C7 cycloalkyl, aryl, heteroaryl or a C1 -C4 alkyl group substituted by one or more substituents selected from C3 -C7 cycloalkyl, C1 -C4 alkoxycarbonyl, aryl or heteroaryl; Z is selected from C1 -C6 alkoxy, aryl (C1 -C4) alkoxy, hydroxy, and --NR4 R5 wherein each of R4 and R5 is independently H or C1 -C6 alkyl, or R4 and R5 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl or N-(C1 -C4 alkyl) piperazinyl group; Y is 1,4 phenylene or pyridine-2,5-diyl, and X is a 5 or 6 membered aromatic heterocyclic group containing one or more nitrogen atoms in its ring; which ring may be fused to a benzene ring or to a further 5- or 6-membered aromatic heterocyclic ring containing one or more nitrogen atoms, at least one of said heterocyclic rings optionally also containing an oxygen or sulphur atom, and being optionally substituted with one or more substituents selected from C1 -C4 alkyl, C1 -C4 alkoxy, halo, CF3 and CN; and their pharmaceutically acceptable salts.